Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints.
about
SUSCEPTIBILITY TEST FOR FUNGI: CLINICAL AND LABORATORIAL CORRELATIONS IN MEDICAL MYCOLOGYCandida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005Rapid susceptibility testing and microcolony analysis of Candida spp. cultured and imaged on porous aluminum oxideEpidemiology of invasive candidiasis: a persistent public health problemCandida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance programCandida rugosa, an emerging fungal pathogen with resistance to azoles: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program.Propofol lipidic infusion promotes resistance to antifungals by reducing drug input into the fungal cellVoriconazole pharmacokinetics and pharmacodynamics in children.In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.Screening for drug-resistant Candida yeasts with chromogenic agar.Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphismCanadian clinical practice guidelines for invasive candidiasis in adults.Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testingIntravenous anidulafungin followed optionally by oral voriconazole for the treatment of candidemia in Asian patients: results from an open-label Phase III trialFrequency of voriconazole resistance in vitro among Spanish clinical isolates of Candida spp. According to breakpoints established by the Antifungal Subcommittee of the European Committee on Antimicrobial Susceptibility Testing.Multilaboratory testing of two-drug combinations of antifungals against Candida albicans, Candida glabrata, and Candida parapsilosisUse of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia.Validation of 24-hour posaconazole and voriconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: application of epidemiological cutoff values to results from a global Candida antifungal surveillance programAntifungal effects on metabolite profiles of medically important yeast species measured by nuclear magnetic resonance spectroscopy.Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods.Antifungal pharmacokinetics and pharmacodynamicsComparative evaluation of Etest and sensititre yeastone panels against the Clinical and Laboratory Standards Institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agentsFluconazole susceptibility and ERG11 gene expression in vaginal candida species isolated from Lagos NigeriaBiofilm production by Candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia.Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testAssessment of accuracy of identification of pathogenic yeasts in microbiology laboratories in the United kingdom.Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida sppComparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia modelIn vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study.In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005.Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole.Developments in the treatment of candidiasis: more choices and new challenges.Non-albicans Candida species in blood stream infections in a tertiary care hospital at New Delhi, India.In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints.Antifungal resistance of Candida glabrata vaginal isolates and development of a quantitative reverse transcription-PCR-based azole susceptibility assay.Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study.
P2860
Q26783197-855C7AA8-3795-4855-B714-EDF986B74E48Q28260910-828CCEB7-CA32-4AAB-8205-86F4CFAE8C39Q28481546-AF564CD5-42B7-4D75-8A29-60DCED808F65Q29616758-4FB6642C-896F-4159-AAAF-25EEAF29B791Q30445376-4B17CE17-7462-4810-A8A5-31C62AD90FB9Q30445379-EFD75D82-4F9B-40F8-879B-931C0D1E293BQ33315163-5F9473E9-77F7-46FB-A29B-CCDCFC20019DQ33577291-D70548A3-4A1E-44B3-A0CB-7190468266B7Q33876423-3C9A3205-761F-4A6C-B1D5-4A86CB6CA6BCQ34009338-EF502217-396A-44DB-8E98-76B97234E264Q34213621-CCE9A8EE-4E42-4D0B-8E36-6B2B4746F1ADQ34237335-58727A0C-81D7-4955-9542-812D37B20EDAQ34529179-FD2588FD-A094-4395-AB73-4D809FE62E6DQ34647337-E649C305-F09F-4AC7-A89A-EECC10EA826BQ34724039-22EA89FF-168D-4198-99B9-4A69D2C0E16BQ34737476-68322EB7-874F-4B30-A61B-71052BB9D2B3Q34737783-252B544F-818F-422A-9E9B-45D8C2628C04Q34933267-835CA9F7-2D5B-473D-B81D-B3698FD36B43Q35067016-1F1F4BAB-946F-4E50-B928-58E713CBEA6BQ35215404-91297597-65E0-4E1F-83D9-319C1C9D5DCAQ35635830-E191A518-DFAA-41C1-923A-6AD200A5D0D3Q35663841-A3253FC1-F385-4BDE-ACEC-BC894AAA91FDQ35690629-F45E8250-7DC2-4D4D-BA5A-A1EA9711E34CQ35862713-CB94DAF9-7873-4220-83CE-4F1ED7579ACAQ35913891-1ACF624D-A72A-42D1-B322-0344CF4723F9Q35913918-9A2C6FD9-5B43-40F8-8185-62A4559D24BEQ36171475-4F6E2344-F54B-4F5A-ABEE-C1FE630DCF7CQ36172242-DD1E1A5A-64FE-430F-8343-706FE935404DQ36314322-55041402-3E6D-4E03-BC47-EA730B6C96DEQ36364009-584616BF-33F6-4BDB-9F11-1A6A50424360Q36414000-96194959-6E67-49D7-890B-8574B831C5DCQ36425025-F5537152-94AA-4303-B637-06298A53107CQ36497888-B6B1CBBD-F1A3-4FA5-A1AC-7FB96B1F4B34Q36608562-21199E25-FA68-40F3-B02A-4BE1AADB42E9Q36623050-DA919910-4EA2-4FB4-ABAB-6F4A6A571063Q36728707-BC6C79EB-5C89-4B89-B110-1F10DBAD6FB4Q36803960-85807250-9BCD-44F7-AB08-A4BFA8733D46Q36845482-A8A360ED-B606-4F99-9FCC-106375B1EE16Q36870890-63776F71-B278-4B57-BC69-2282B0FEDF25Q36898200-9052F284-8A5E-4C97-9CE6-064B740325A7
P2860
Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մարտին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Correlation of MIC with outcom ...... for interpretive breakpoints.
@ast
Correlation of MIC with outcom ...... for interpretive breakpoints.
@en
Correlation of MIC with outcom ...... for interpretive breakpoints.
@nl
type
label
Correlation of MIC with outcom ...... for interpretive breakpoints.
@ast
Correlation of MIC with outcom ...... for interpretive breakpoints.
@en
Correlation of MIC with outcom ...... for interpretive breakpoints.
@nl
prefLabel
Correlation of MIC with outcom ...... for interpretive breakpoints.
@ast
Correlation of MIC with outcom ...... for interpretive breakpoints.
@en
Correlation of MIC with outcom ...... for interpretive breakpoints.
@nl
P2093
P2860
P1476
Correlation of MIC with outcom ...... for interpretive breakpoints.
@en
P2093
A Espinel-Ingroff
D J Diekema
D J Sheehan
D W Warnock
E M Johnson
M A Ghannoum
M A Pfaller
P2860
P304
P356
10.1128/JCM.44.3.819-826.2006
P407
P577
2006-03-01T00:00:00Z